JHP Pharmaceuticals to Produce Lyophilized Biologic for Late-Phase Trials

JHP Pharmaceuticals, a provider of global contract manufacturing services for sterile products, has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase clinical trials.
Stuart Hinchen president and CEO of JHP stated, "We know that customers want to seamlessly progress from clinical batch production to product launch and then commercialization.  JHP's established infrastructure and expertise transitioning products from clinical to commercial supply are recognized by customers looking for long-term reliability and continuity when selecting a contract manufacturing organization.  Additionally, our cGMP compliance record and experienced staff allows customers to focus on their pressing business needs with confidence."
The Parsippany, NJ-based firm has successfully supported launches of several products in US and international markets and manufactures products for sale in 86 countries.  JHP's Rochester, Michigan manufacturing site's 25-year history in contract manufacturing is a result of a solid cGMP compliance record, a quality-driven experienced staff and a customer-centric approach.
JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations.
JHP's sterile manufacturing facility, located in Rochester, Michigan utilizes three high-speed filling lines, a clinical filling line, and four lyophilizers.  The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.  JHP has the capability to manufacture small-scale clinical through large-scale commercial products. 
 
No votes yet